-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The global monoclonal antibodies (mAbs) market is expected to reach $494.
53 billion by 2030, growing at a compound annual growth rate (CAGR) of 11.
30%
during the forecast period.
Increasing R&D activities to develop novel therapeutic monoclonal antibodies and government support initiatives for biologics manufacturing will drive the market growth
.
53 billion by 2030, growing at a compound annual growth rate (CAGR) of 11.
30%
during the forecast period.
Increasing R&D activities to develop novel therapeutic monoclonal antibodies and government support initiatives for biologics manufacturing will drive the market growth
.
Research and Market, a well-known industry intelligence agency, recently made the above forecast
in its "Monoclonal Antibody Market Size, Share and Trend Analysis Report 2022-2030 (by Source Type (Chimerism, Mouse, Humanization, Humanization), Production Type (In Vivo, In Vitro, In Vitro), Application, End Use, Region and Segment Market Forecast)".
The growing demand for personalized medicines is likely to positively impact
the development of therapeutic mAb-targeted therapies tailored to individual needs.
In addition, the therapeutic application of monoclonal antibodies has many advantages over traditional treatment regimens, such as few adverse reactions, strong therapeutic specificity, and strong large-scale production capacity, and can significantly drive market growth
.
In addition, several government entities are driving clinical research activities and expanding the use of
monoclonal antibody therapies.
For example, in June 2022, the National Institutes of Health launched a clinical trial evaluating duplimab (Dupixent/dapitox, Sanofi) to reduce asthma attacks and improve lung function
in children.
Similarly, in March 2021, the U.
S.
Department of Health and Human Services (U.
S.
The Department of Health and Human Services invested $150 million to increase patients' access to
monoclonal antibody therapy.
These initiatives are expected to increase the use of monoclonal antibodies and enhance growth prospects
.
In addition, technological advances in genetic engineering, DNA cloning, and various peptide and protein display technologies have facilitated the generation and optimization
of recombinant monoclonal antibodies.
The demand for this recombinant antibody is driven by the growing commercial outlook and quality requirements that hybridoma technology may not be able to meet
.
Thus, the market is expected to grow
significantly as the commercial viability of restructuring techniques improves.
The pandemic has created some market expansion opportunities
by driving the development of several monoclonal antibodies against the SARS-CoV-2 virus.
Because monoclonal antibodies are a promising alternative to disease mitigation due to their safety and efficacy, several monoclonal antibodies, such as Eli Lilly's Bebtelovimab and GlaxoSmithKline's Sotrovitab, have received emergency use authorization
from the US FDA.
Such licensing is likely to broaden the growth prospects for monoclonal antibody applications and drive the market growth
.
The Monoclonal Antibodies market report has the following highlights:
The Monoclonal Antibodies market report has the following highlights: From the perspective of source type, due to the low immunogenicity of antibodies and the increasing application in cancer treatment, humanized monoclonal antibody fragments accounted for the largest share in 2021, accounting for 54.
07%.
07%.
Due to the low pollution level and advanced biomanufacturing capabilities offered by the technology, in vitro production type accounted for a dominant share
of 78.
45% in 2021.
of 78.
45% in 2021.
In 2021, the oncology segment dominated the market due to the increasing number of approvals for monoclonal antibody cancer therapies and increasing scientific and patient awareness of such therapies
.
.
In 2021, hospitals accounted for the largest
share of the end-use segment due to the widespread use of monoclonal antibodies in hospital cancer treatment and increasing healthcare expenditures favoring the adoption of such therapies.
share of the end-use segment due to the widespread use of monoclonal antibodies in hospital cancer treatment and increasing healthcare expenditures favoring the adoption of such therapies.
In 2021, North America accounted for 46.
2%
of the market value due to the availability of advanced healthcare infrastructure, high growth in cancer incidence, and the presence of key companies such as Pfizer, Amgen, and Merck.
2%
of the market value due to the availability of advanced healthcare infrastructure, high growth in cancer incidence, and the presence of key companies such as Pfizer, Amgen, and Merck.
Asia Pacific is expected to have the highest growth rate during the forecast period due to the large number of cancer treatment patients in the region and the expanding
clinical research prospects of monoclonal antibodies.
clinical research prospects of monoclonal antibodies.
